Peptide Vaccine for Cancer Prevention Shows 100% Immune Response in Lynch Syndrome Carriers | Research

The takeaway

Nous-209, a neoantigen vaccine encoding 209 frameshift peptides, was safe and triggered neoantigen-specific immune responses in 100% of evaluable Lynch syndrome carriers, with immunity lasting at least one year.

100% immune response
Every evaluable participant developed neoantigen-specific T cell immunity targeting cancer-associated frameshift peptides

What the researchers found

100% of evaluable participants (37/37) developed neoantigen-specific immune responses, with a mean peak of ~1,100 interferon-γ spot-forming cells per million PBMCs, and 85% maintained detectable immunity at one year.

Why it matters

If this vaccine can prevent cancer in Lynch syndrome carriers, it would represent a paradigm shift from treating cancer to intercepting it before it develops—potentially benefiting millions of people with this common genetic condition.

How the study worked

Phase 1b/2 single-arm clinical trial (NCT05078866) with 45 Lynch syndrome carriers receiving heterologous prime-boost vaccination. Safety and immunogenicity were coprimary endpoints.

What this study cannot tell us

Phase 1b/2 trial — cancer prevention efficacy cannot be assessed from immunogenicity data alone. Single-arm design without placebo control. Small sample size. Long-term cancer incidence outcomes are still pending.

How to read the evidence

Phase 1b/2 clinical trial demonstrating safety and immunogenicity. Encouraging but cancer prevention efficacy requires longer follow-up and larger trials.

When this study was published

Published in 2025, representing one of the first clinical demonstrations of neoantigen-directed cancer interception.

The bigger picture

Cancer interception through peptide-based vaccines is an emerging frontier. Success in Lynch syndrome could pave the way for similar neoantigen vaccines in other hereditary cancer syndromes and potentially for microsatellite-unstable cancers in the general population.

Questions still open

Will the neoantigen-specific immune responses translate into actual cancer prevention in Lynch syndrome carriers?
How long does vaccine-induced immunity persist beyond one year, and will booster doses be needed?
Could this approach be adapted for other microsatellite-unstable cancers outside of Lynch syndrome?

Common questions

How does this vaccine prevent cancer?

Lynch syndrome causes DNA repair defects that produce abnormal frameshift peptides in precancerous cells. The Nous-209 vaccine trains your immune system to recognize and attack cells displaying these peptides, potentially destroying precancers before they become full cancers.

Is this vaccine available now?

Not yet. This is an early-phase clinical trial showing the vaccine is safe and triggers immune responses. Larger trials are needed to prove it actually prevents cancer before it can be approved for clinical use.

Read the original research

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Nature medicine

View on PubMed ↗Publisher’s paper ↗

Citation

D'Alise, Anna Morena; Willis, Jason; Duzagac, Fahriye; Hall, Michael J; Cruz-Correa, Marcia; Idos, Gregory E; Thirumurthi, Selvi; Ballester, Veroushka; Leoni, Guido; Garzia, Irene; Antonucci, Laura; De Marco, Lorenzo; Micarelli, Elisa; Deng, Nan; Seclì, Laura; Gogov, Sven; Dong, Wenli; Jack Lee, J; Bowen, Charles M; Vornik, Lana A; Garcia-Gonzalez, Araceli; Reyes-Uribe, Laura; Richmond, Ellen; Umar, Asad; Brown, Powel H; Sinha, Krishna M; Rodriguez, Luz Maria; Scarselli, Elisa; Vilar, Eduardo. (2026). Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.. Nature medicine. https://doi.org/10.1038/s41591-025-04182-9